Law of the People's Republic of China on Traditional Chinese Medicine, brings new opportunities for innovation and the internalization of traditional Chinese medicine (TCM).

After receiving Certification of Suitability to Monograph from the European Pharmacopoeia (CEP), Baiyunshan Hanfang Pharmaceutical Co., Limited (Hanfang) is striving to build up high-end TCM products that are considered relevant in the modern world.  

Representative of Marshall University and Yuancheng (L), Chairman of the board of Baiyuanshan Hanfang (R).

In recent years, as the TCM’s top-level design has increasingly improved, the PRC has published new laws regarding Traditional Chinese Medicine, providing top-level guidance and insurance for the innovation and internationalization of TCM.  

To implement this kind of approach GPHL has proposed making TCM ‘hip’ and will strive to bring TCM to the world stage through cutting edge, relevant marketing.

The GPHL Ganoderma Lucidum Spore Oil Soft Capsule (for boosting immunity), combines a traditional remedy with modern TCM technology, leading the trend in TCM development, looking for new ways to present traditional products. Meanwhile, Hanfang just acquired the CEP approval by European Directorate for the Quality Control of Medicines (EDOM) on another product, marking a significant milestone on GPHL’s way towards European Union market and even the global market.  

Granted nine new patents.

GPHL Ganoderma Lucidum Spore Oil Soft Capsule marks a milestone for high-end TCM development.

Li Chuyuan, Chairman of GPHL, believes that “Trendy TCM” are the most sought after health products for people with the most advanced science and technology. GPHL Ganoderma Lucidum Spore Oil Soft Capsule epitomizes Li’s statement.  

GPHL’s Ganoderma Lucidum Spore Oil Soft Capsule is a high-end product made in line with stringent quality control system adopting even stricter standards than GMP due to technology available exclusively to Hanfang. So far, Hanfang has acquired 11 international PCT patents and 9 national patents including freezing ultra-micro cellwall-breaking technology, high-pressure and low-temperature supercritical fluid extraction technology.      

Guangzhou Hanfang Pharmaceutical Co., Ltd. (Hanfang), a subsidiary of Guangzhou Pharmaceutical Holdings Ltd, is the only national engineering research and industry demonstration center for the modernization of the extraction and separation of traditional Chinese medicine (TCM) ingredients in China. It is a Guangdong firm known for its innovation.

Hanfang has invested nearly 300 million RMB in its research center and industrial base, concentrating on developing and producing natural medicine, botanical pharmaceutical ingredients, natural healthcare products and preparations as well as offering technological services for clients at home and abroad.

CEP approved quality control system.

Internationally recognized modernization of TCM.  

Over recent years, the TCM industry has gained national attention by acquiring governmental investment and policy support. In recent years, TCM has accomplished a great deal and received increasing worldwide recognition.

Recently, GPHL has made exciting breakthroughs in terms of TCM modernization and internationalization. Baiyunshan Hanfang Botanical Anti-tumor Drug has been CEP approved by EDOM. The CEP is the European Union’s permit for drugs to enter EU market. CEP, one of the highest standard certifications, exacts strict requirements on system quality and quality control, and is commonly deemed a ‘green card’ allowing entry to both European and American markets.

GPHL Ganoderma Lucidum Spore Oil Soft Capsule is currently the only one produced by an enterprise with CEP approval, gaining popularity at home and overseas.

By getting the CEP approval, Baiyunshan Hanfang Botanical Anti-tumor Drug has demonstrated its world-leading position regarding innovation, quality systems and quality control. Furthermore, it is the first time that a Guangdong enterprise has acquired such certification for botanical anti-tumor drugs, making it a significant milestone for GPHL’s internationalization drive.

Going global is an important part of GPHL’s Trendy TCM stratagem. “A growing number of Western pharmaceutical giants are stepping up their investment in TCM industry in China,” said Li Chuyuan. Over the recent years, GPHL has attended some international forums like World Economic Forum, APEC Summit and Boao Forum for Asia, promoting the idea of Trendy TCM on the international stage.  

Daily Telegraph, if TCM is China’s answer to the needs in the global health market, then GPHL’s “Trendy TCM” will take it further.

GPHL has undertaken the first research into tumor fighting properties of ganoderma lucidum spore oil.

Technological advance is a huge plus point for popularizing TCM.

As the quality of scientific research and the clinical success of TCM increases, TCM is going global with a brand new look.

Hanfang has always taken advantage of its technological accomplishment to move the modernization of TCM forward. At the beginning of 2016, it established the National Engineering Research Center for Tumor Immunity with Sun Yan, the founder of China’s medical oncology and academician of the Chinese Academy of Engineering as the chief scientist. In March, 2017, Hanfang initiated the first world’s research into the preventative properties of ganoderma lucidum spore oil in terms of tumor development, aiming to tackle the problem of tumor cell’s resistance to drugs.

A professor of Marshall University conducted in vitro experiments into the unique properties of GPHL Ganoderma Lucidum Spore Oil Soft Capsules and their medical potential. After seeing preliminary results, he offered to conduct further research with Hanfang into the possibilities that these capsules can aid the body in resisting the buildup of cancerous cells.

The USA representative believes that Chinese herbal remedies are rich in potential, they are very optimistic about the research on TCM’s application to tumor prevention and treatment. Baiyunshan Hanfang represents a high-level research platform in the realm of TCM R&D. The cooperation marks an important step toward better treatment of tumors and development of tumor preventives. This  research is expected to make great contribution to tackling the drug resistance of tumor cells.

Multiple achievements have demonstrated GPHL’s constant pursuit of excellence including: the CEP approval; the world leading research on the application of ganoderma lucidum spore oil to tumor prevention and large scale clinical studies. Due to the company’s quality conscious technology based approach, Hanfang always engages in the frontiers of TCM development acting as a pioneer of TCM modernization and spokesman for TCM internationalization.

According to Li Chuyuan, the TCM industry still has a long way to go. The concept of “Trendy TCM” has become the buzzword for the transformation and modernization of the TCM Sector of GPHL. Li is confident that the global market will soon have a greater understanding of TCM and Chinese healthcare ideas, and that GPHL will make it into the Fortune Global 500 in the next phase.

(Translator: Cheryl Ma; Editors: Simon Haywood, Olivia Yang, Monica Liu)